Identification of cerebral spinal fluid protein biomarkers in Niemann-Pick disease, type C1
Abstract Background Niemann-Pick disease, type C1 (NPC1) is an ultrarare, recessive, lethal, lysosomal disease characterized by progressive cerebellar ataxia and cognitive impairment. Although the NPC1 phenotype is heterogeneous with variable age of onset, classical NPC1 is a pediatric disorder. Cur...
| Main Authors: | , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2023-01-01
|
| Series: | Biomarker Research |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s40364-023-00448-x |
| _version_ | 1811171635578798080 |
|---|---|
| author | Kiersten Campbell Niamh X. Cawley Rachel Luke Katelin E. J. Scott Nicholas Johnson Nicole Y. Farhat Derek Alexander Christopher A. Wassif Wenping Li Stephanie M. Cologna Elizabeth Berry-Kravis An Dang Do Ryan K. Dale Forbes D. Porter |
| author_facet | Kiersten Campbell Niamh X. Cawley Rachel Luke Katelin E. J. Scott Nicholas Johnson Nicole Y. Farhat Derek Alexander Christopher A. Wassif Wenping Li Stephanie M. Cologna Elizabeth Berry-Kravis An Dang Do Ryan K. Dale Forbes D. Porter |
| author_sort | Kiersten Campbell |
| collection | DOAJ |
| description | Abstract Background Niemann-Pick disease, type C1 (NPC1) is an ultrarare, recessive, lethal, lysosomal disease characterized by progressive cerebellar ataxia and cognitive impairment. Although the NPC1 phenotype is heterogeneous with variable age of onset, classical NPC1 is a pediatric disorder. Currently there are no therapies approved by the FDA and therapeutics trials for NPC1 are complicated by disease rarity, heterogeneity, and the relatively slow rate of neurological decline. Thus, identification of disease relevant biomarkers is necessary to provide tools that can support drug development efforts for this devastating neurological disease. Methods Proximal extension assays (O-link® Explore 1536) were used to compare cerebrospinal fluid (CSF) samples from individuals with NPC1 enrolled in a natural history study and non-NPC1 comparison samples. Relative expression levels of 1467 proteins were determined, and candidate protein biomarkers were identified by evaluating fold-change and adjusted Kruskal–Wallis test p-values. Selected proteins were orthogonally confirmed using ELISA. To gain insight into disease progression and severity we evaluated the altered protein expression with respect to clinically relevant phenotypic aspects: NPC Neurological Severity Score (NPC1 NSS), Annual Severity Increment Score (ASIS) and age of neurological onset. Results This study identified multiple proteins with altered levels in CSF from individuals with NPC1 compared to non-NPC1 samples. These included proteins previously shown to be elevated in NPC1 (NEFL, MAPT, CHIT1, CALB1) and additional proteins confirmed by orthogonal assays (PARK7, CALB2/calretinin, CHI3L1/YKL-40, MIF, CCL18 and ENO2). Correlations with clinically relevant phenotypic parameters demonstrated moderate negative (p = 0.0210, r = -0.41) and possible moderate positive (p = 0.0631, r = 0.33) correlation of CSF CALB2 levels with age of neurological onset and ASIS, respectively. CSF CHI3L1 levels showed a moderate positive (p = 0.0183, r = 0.40) correlation with the concurrent NPC1 NSS. A strong negative correlation (p = 0.0016, r = -0.648) was observed between CSF CCL18 and age of neurological onset for childhood/adolescent cases. CSF CCL18 levels also showed a strong positive correlation (p = 0.0017, r = 0.61) with ASIS. Conclusion Our study identified and validated multiple proteins in CSF from individuals with NPC1 that are candidates for further investigation in a larger cohort. These analytes may prove to be useful as supportive data in therapeutic trials. Trial registrations NCT00344331, NCT00001721, NCT02931682. |
| first_indexed | 2024-04-10T17:17:22Z |
| format | Article |
| id | doaj.art-8ae5ae9914ad4795b2ed86f8f4902c36 |
| institution | Directory Open Access Journal |
| issn | 2050-7771 |
| language | English |
| last_indexed | 2024-04-10T17:17:22Z |
| publishDate | 2023-01-01 |
| publisher | BMC |
| record_format | Article |
| series | Biomarker Research |
| spelling | doaj.art-8ae5ae9914ad4795b2ed86f8f4902c362023-02-05T12:19:40ZengBMCBiomarker Research2050-77712023-01-0111111910.1186/s40364-023-00448-xIdentification of cerebral spinal fluid protein biomarkers in Niemann-Pick disease, type C1Kiersten Campbell0Niamh X. Cawley1Rachel Luke2Katelin E. J. Scott3Nicholas Johnson4Nicole Y. Farhat5Derek Alexander6Christopher A. Wassif7Wenping Li8Stephanie M. Cologna9Elizabeth Berry-Kravis10An Dang Do11Ryan K. Dale12Forbes D. Porter13Bioinformatics and Scientific Programming Core, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of HealthSection On Molecular Dysmorphology, Division of Translational Research, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of HealthSection On Molecular Dysmorphology, Division of Translational Research, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of HealthSection On Molecular Dysmorphology, Division of Translational Research, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of HealthBioinformatics and Scientific Programming Core, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of HealthSection On Molecular Dysmorphology, Division of Translational Research, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of HealthSection On Molecular Dysmorphology, Division of Translational Research, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of HealthSection On Molecular Dysmorphology, Division of Translational Research, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of HealthDepartment of Chemistry and Laboratory of Integrative Neuroscience, University of Illinois ChicagoDepartment of Chemistry and Laboratory of Integrative Neuroscience, University of Illinois ChicagoRush University Medical CenterUnit On Cellular Stress in Development and Diseases, Division of Translational Research, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of HealthBioinformatics and Scientific Programming Core, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of HealthSection On Molecular Dysmorphology, Division of Translational Research, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of HealthAbstract Background Niemann-Pick disease, type C1 (NPC1) is an ultrarare, recessive, lethal, lysosomal disease characterized by progressive cerebellar ataxia and cognitive impairment. Although the NPC1 phenotype is heterogeneous with variable age of onset, classical NPC1 is a pediatric disorder. Currently there are no therapies approved by the FDA and therapeutics trials for NPC1 are complicated by disease rarity, heterogeneity, and the relatively slow rate of neurological decline. Thus, identification of disease relevant biomarkers is necessary to provide tools that can support drug development efforts for this devastating neurological disease. Methods Proximal extension assays (O-link® Explore 1536) were used to compare cerebrospinal fluid (CSF) samples from individuals with NPC1 enrolled in a natural history study and non-NPC1 comparison samples. Relative expression levels of 1467 proteins were determined, and candidate protein biomarkers were identified by evaluating fold-change and adjusted Kruskal–Wallis test p-values. Selected proteins were orthogonally confirmed using ELISA. To gain insight into disease progression and severity we evaluated the altered protein expression with respect to clinically relevant phenotypic aspects: NPC Neurological Severity Score (NPC1 NSS), Annual Severity Increment Score (ASIS) and age of neurological onset. Results This study identified multiple proteins with altered levels in CSF from individuals with NPC1 compared to non-NPC1 samples. These included proteins previously shown to be elevated in NPC1 (NEFL, MAPT, CHIT1, CALB1) and additional proteins confirmed by orthogonal assays (PARK7, CALB2/calretinin, CHI3L1/YKL-40, MIF, CCL18 and ENO2). Correlations with clinically relevant phenotypic parameters demonstrated moderate negative (p = 0.0210, r = -0.41) and possible moderate positive (p = 0.0631, r = 0.33) correlation of CSF CALB2 levels with age of neurological onset and ASIS, respectively. CSF CHI3L1 levels showed a moderate positive (p = 0.0183, r = 0.40) correlation with the concurrent NPC1 NSS. A strong negative correlation (p = 0.0016, r = -0.648) was observed between CSF CCL18 and age of neurological onset for childhood/adolescent cases. CSF CCL18 levels also showed a strong positive correlation (p = 0.0017, r = 0.61) with ASIS. Conclusion Our study identified and validated multiple proteins in CSF from individuals with NPC1 that are candidates for further investigation in a larger cohort. These analytes may prove to be useful as supportive data in therapeutic trials. Trial registrations NCT00344331, NCT00001721, NCT02931682.https://doi.org/10.1186/s40364-023-00448-xNiemann-Pick diseaseType C1Proximal extension assayBiomarkersCerebrospinal fluidCCL18 |
| spellingShingle | Kiersten Campbell Niamh X. Cawley Rachel Luke Katelin E. J. Scott Nicholas Johnson Nicole Y. Farhat Derek Alexander Christopher A. Wassif Wenping Li Stephanie M. Cologna Elizabeth Berry-Kravis An Dang Do Ryan K. Dale Forbes D. Porter Identification of cerebral spinal fluid protein biomarkers in Niemann-Pick disease, type C1 Biomarker Research Niemann-Pick disease Type C1 Proximal extension assay Biomarkers Cerebrospinal fluid CCL18 |
| title | Identification of cerebral spinal fluid protein biomarkers in Niemann-Pick disease, type C1 |
| title_full | Identification of cerebral spinal fluid protein biomarkers in Niemann-Pick disease, type C1 |
| title_fullStr | Identification of cerebral spinal fluid protein biomarkers in Niemann-Pick disease, type C1 |
| title_full_unstemmed | Identification of cerebral spinal fluid protein biomarkers in Niemann-Pick disease, type C1 |
| title_short | Identification of cerebral spinal fluid protein biomarkers in Niemann-Pick disease, type C1 |
| title_sort | identification of cerebral spinal fluid protein biomarkers in niemann pick disease type c1 |
| topic | Niemann-Pick disease Type C1 Proximal extension assay Biomarkers Cerebrospinal fluid CCL18 |
| url | https://doi.org/10.1186/s40364-023-00448-x |
| work_keys_str_mv | AT kierstencampbell identificationofcerebralspinalfluidproteinbiomarkersinniemannpickdiseasetypec1 AT niamhxcawley identificationofcerebralspinalfluidproteinbiomarkersinniemannpickdiseasetypec1 AT rachelluke identificationofcerebralspinalfluidproteinbiomarkersinniemannpickdiseasetypec1 AT katelinejscott identificationofcerebralspinalfluidproteinbiomarkersinniemannpickdiseasetypec1 AT nicholasjohnson identificationofcerebralspinalfluidproteinbiomarkersinniemannpickdiseasetypec1 AT nicoleyfarhat identificationofcerebralspinalfluidproteinbiomarkersinniemannpickdiseasetypec1 AT derekalexander identificationofcerebralspinalfluidproteinbiomarkersinniemannpickdiseasetypec1 AT christopherawassif identificationofcerebralspinalfluidproteinbiomarkersinniemannpickdiseasetypec1 AT wenpingli identificationofcerebralspinalfluidproteinbiomarkersinniemannpickdiseasetypec1 AT stephaniemcologna identificationofcerebralspinalfluidproteinbiomarkersinniemannpickdiseasetypec1 AT elizabethberrykravis identificationofcerebralspinalfluidproteinbiomarkersinniemannpickdiseasetypec1 AT andangdo identificationofcerebralspinalfluidproteinbiomarkersinniemannpickdiseasetypec1 AT ryankdale identificationofcerebralspinalfluidproteinbiomarkersinniemannpickdiseasetypec1 AT forbesdporter identificationofcerebralspinalfluidproteinbiomarkersinniemannpickdiseasetypec1 |